Select the incorrect statements with reference to Rh grouping.
A. Erythroblastosis foetalis is a condition observed having foetus with Rh−ve blood and mother with Rh+ve blood.
B. Rh antigen is observed on RBCs in the majority of human beings.
C. Before blood transfusion, Rh group should also be matched.
D. Rh incompatibility is observed when a pregnant mother is Rh−ve and the foetus is Rh+ve.
E. Erythroblastosis foetalis can be avoided by administering anti-Rh antibodies to the mother immediately after the delivery of the second child.
Choose the answer from the options given below:
Solution :
The question asks which statements about the Rh blood group are incorrect.
Let's evaluate each statement one by one.
Statement A: “Erythroblastosis foetalis is a condition observed having foetus with Rh−ve blood and mother with Rh+ve blood.”
This is wrong. Erythroblastosis fetalis (also called hemolytic disease of the newborn) occurs when the mother is Rh‑negative and the fetus is Rh‑positive. The mother’s immune system can produce anti‑D antibodies that cross the placenta and destroy fetal red cells. Therefore, the correct situation is the opposite of what statement A describes.
Statement B: “Rh antigen is observed on RBCs in the majority of human beings.”
This is correct. Approximately 85 % of people worldwide express the Rh (D) antigen on their red blood cells, so it is indeed present in the majority of the population.
Statement C: “Before blood transfusion, Rh group should also be matched.”
This is correct. In addition to ABO compatibility, Rh (especially the D antigen) must be matched to avoid hemolytic reactions in Rh‑negative recipients receiving Rh‑positive blood.
Statement D: “Rh incompatibility is observed when a pregnant mother is Rh‑ve and the foetus is Rh+ve.”
This is correct. Rh incompatibility arises precisely when an Rh‑negative mother carries an Rh‑positive fetus, leading to possible allo‑immunisation.
Statement E: “Erythroblastosis foetalis can be avoided by administering anti‑Rh antibodies to the mother immediately after the delivery of the second child.”
This is incorrect. The preventive measure is to give anti‑D immunoglobulin (Rho(D) immune globulin) to an Rh‑negative mother **after the first Rh‑positive delivery**, not after the second child. The purpose is to neutralize any fetal Rh‑positive cells before the mother’s immune system can become sensitised. Giving it after the second child would be too late to prevent the first sensitisation.
Summarising the evaluations:
Hence the answer that lists the incorrect statements is A and E only.
Completely free for students. Educators & coaching institutes get 2 months free Pro trial to create tests.
Access unlimited practice questions, detailed step-by-step solutions, and exam study materials — completely free for students.
Create and conduct professional online assessments with AI question generation, tab proctoring, and comprehensive batch management.
Prepare effectively with the CBSE Class 12 Biology 2022–23 Set - 1 Question Paper. This paper is ideal for students appearing for the CBSE Class 12 Board Examination and helps in understanding the latest exam pattern, question types, and marking scheme. Practice with authentic board-level questions to improve accuracy, time management, and conceptual clarity. The paper includes detailed solutions to help you analyze your performance and strengthen important Biology concepts before the exam.
Practice with the CBSE Class 12 Biology 2022–23 Set - 2 Question Paper to strengthen your preparation for the CBSE Board Examination. This previous year question paper follows the latest CBSE exam pattern and includes a variety of board-level questions covering Genetics, Evolution, Biotechnology, Human Physiology, Reproduction, Ecology, and other important topics. Detailed solutions help you understand the correct approach, improve conceptual clarity, and enhance time management for the final exam. Solving this paper is an excellent way to evaluate your preparation and boost your confidence before the board examination.
Copyright © 2026 Combe Labs Private Limited. All Rights Reserved.